Completed NA INTERVENTIONAL 1-arm NCT04246021

Use of Intravenous Ferric Carboxymaltose in Treatment of Anemia in Cancer Patients Undergoing Chemotherapy

The Use of Intravenous Ferric Carboxymaltose (FCM) Without Erythropoiesis-stimulating Agents (ESA) in the Treatment of Anemia in Cancer Patients Undergoing Chemotherapy With or Without Radiotherapy

Sponsor: Hikma Pharmaceuticals LLC

Conditions Anemia Cancer

Interventions Ferric carboxymaltose (FCM)

Updated 5 times since 2020 Last updated: Dec 8, 2021 Started: Jun 15, 2016 Primary completion: Dec 31, 2017 Completion: Dec 31, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A NA clinical study on Anemia and Cancer, this trial is completed. The trial is conducted by Hikma Pharmaceuticals LLC and has accumulated 5 data snapshots since 2016. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2022 — Jul 2024 [monthly]

Completed NA
Jan 2021 — Jan 2022 [monthly]

Completed NA
Feb 2020 — Jan 2021 [monthly]

Completed NA

First recorded

Jun 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hikma Pharmaceuticals LLC
King Hussein Cancer Center

Data source: King Hussein Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.